Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Kirwan

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|September 8, 2004
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trialPhilip A Poole-Wilson, Jacobus Lubsen, Bridget-Anne Kirwan, et al.
Lancet (London, England)|August 30, 2018
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trialFriedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Clinical Trials (London, England)|August 21, 2020
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trialBrett L Houston, Patrick R Lawler, Ewan C Goligher, et al.
JAMA|October 11, 2021
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical TrialJean M Connors, Maria M Brooks, Frank C Sciurba, et al.
Circulation|June 25, 2023
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled TrialScott D Solomon, Charles J Lowenstein, Ankeet S Bhatt, et al.
Journal of the American Medical Directors Association|June 7, 2011
Sarcopenia with limited mobility: an international consensusJohn E Morley, Angela Marie Abbatecola, Josep M Argiles, et al.
European Heart Journal|June 3, 2021
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF studyEwa A Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, et al.
JAMA|January 18, 2022
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical TrialJeffrey S Berger, Lucy Z Kornblith, Michelle N Gong, et al.
Lancet (London, England)|November 16, 2020
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialPiotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trialMikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|September 8, 2004
Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trialPhilip A Poole-Wilson, Jacobus Lubsen, Bridget-Anne Kirwan, et al.
Lancet (London, England)|August 30, 2018
Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trialFriedrich Koehler, Kerstin Koehler, Oliver Deckwart, et al.
Clinical Trials (London, England)|August 21, 2020
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trialBrett L Houston, Patrick R Lawler, Ewan C Goligher, et al.
JAMA|October 11, 2021
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical TrialJean M Connors, Maria M Brooks, Frank C Sciurba, et al.
Circulation|June 25, 2023
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled TrialScott D Solomon, Charles J Lowenstein, Ankeet S Bhatt, et al.
Journal of the American Medical Directors Association|June 7, 2011
Sarcopenia with limited mobility: an international consensusJohn E Morley, Angela Marie Abbatecola, Josep M Argiles, et al.
European Heart Journal|June 3, 2021
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF studyEwa A Jankowska, Bridget-Anne Kirwan, Mikhail Kosiborod, et al.
JAMA|January 18, 2022
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical TrialJeffrey S Berger, Lucy Z Kornblith, Michelle N Gong, et al.
Lancet (London, England)|November 16, 2020
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trialPiotr Ponikowski, Bridget-Anne Kirwan, Stefan D Anker, et al.
The Lancet. Diabetes & Endocrinology|September 9, 2024
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trialMikhail N Kosiborod, Sheryl L Windsor, Orly Vardeny, et al.
Pageof 7